Roche to Phase out Chip-Based Sequence Capture; Peptide Arrays 'Close' to Commercialization | GenomeWeb

When Roche stops making NimbleGen DNA microarrays at the end of this year, its sequence capture chips will also no longer be available. At the same time, the company will continue to use the NimbleGen brand with its in-solution target enrichment products, and is close to launching a new, high-density peptide array platform, according to a company official.

Thomas Schinecker, head of Roche's Sequencing Solutions business, told BioArray News this week that the firm will no longer offer array-based sequence capture to clients after Dec. 31.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.